Shanghai Fosun Pharmaceutical (600196.SH): The drug registration application for Cisplatin Injection has been accepted.

Shanghai Fosun Pharmaceutical (600196.SH) announced that its wholly-owned subsidiary, Jissmei (Wuhan) Pharmaceutical Co., Ltd., has recently had its drug registration application for self-developed cisplatin injection ("the new drug") accepted by the National Medical Products Administration. It is reported that the new drug is a chemotherapeutic drug developed independently by the group (including the company and its subsidiary/units). The new drug is intended to (1) be used in combination therapy with other approved chemotherapy drugs in patients with metastatic testicular tumors who have already undergone appropriate surgery and/or radiation therapy; (2) be used as adjunctive therapy in patients with metastatic ovarian tumors who have not previously received treatment with cisplatin injection and have difficulty responding to standard chemotherapy or in combination therapy with other approved chemotherapy drugs in patients with metastatic ovarian tumors who have already undergone appropriate surgery and/or radiation therapy (combinations already established include the new drug and cyclophosphamide); (3) be used in patients with advanced bladder cancer who are no longer suitable for local treatment (such as surgery and/or radiation therapy).